Transgenically Produced Biopharmaceuticals Could Soar to $12 Billion by 2012

New York, February 27, 2006 — With the possibility of the world’s first transgenic plant-produced biopharmaceutical being approved for use this year, worldwide attention is focusing on the futuristic breakthroughs that could dramatically alter the biopharm manufacturing landscape and drive sales past the $12 billion mark by 2012, according to a new study from market research firm Kalorama Information, a division of MarketResearch.com, a leading provider of industry-specific market research reports.

By using animal and plant platforms as bioreactors rather than established production technologies, which use bacteria, yeast, and cultured mammalian cells, the potential to provide large quantities of complex proteins in a more cost-effective manner has arrived.

The new study, Transgenic Animals and Plants in Pharmaceutical Research and Manufacturing, predicts that with anticipated EMEA and FDA approval of several such drugs this year, the market is expected to reach $225 million. Further refining of such technology and the anticipated approval of other plant- and animal-derived drugs currently in clinical trials are expected to grow the market by 140% over the next six years.

“The future is already here and producing biopharmaceuticals through newer methodologies which utilize the lower-cost genetic capabilities of plants and animals as opposed to the enormously expensive current methods of cell culture production simply makes sense,” notes Anne Anscomb, the report’s author. “Over the next several years, as more and more of these drugs are approved worldwide, we should begin to see such transgenic manufacturing becoming an industry standard which will help to keep these high-tech drugs affordable.”

The study provides a comprehensive analysis of the current status of the subsector of the biopharmaceutical industry focused on animal and plant transgenics for biopharmaceutical production and research. It includes an in-depth look at current drugs in the pipeline, key manufacturers spearheading research and production, cost analysis of mammalian, avian, and plant platforms versus traditional methods of microbial fermentation and mammalian cell culture, and sales projections through 2015.

Transgenic Animals and Plants in Pharmaceutical Research and Manufacturing can be purchased directly from Kalorama Information by clicking http://www.kaloramainformation.com/pub/1186400.html. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent market research for the life sciences. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.